Injectable Wireless Device Enables Non‑Surgical Nerve Control for Pain and Movement Disorders

How the Implant Operates Without Wires or Batteries

Researchers at New York University Abu Dhabi, together with clinicians from Cleveland Clinic Abu Dhabi, unveiled a miniature injectable device on June 12, 2026. The technology promises to modulate nerve signals without traditional surgery, external wires, or implanted batteries. Early trials suggest it could treat chronic pain and certain movement disorders.

Current neuromodulation therapies rely on bulky implants that require open‑chest surgery and periodic battery replacements. The new device sidesteps these hurdles by using a wireless power link that activates a micro‑circuit once it is injected near the target nerve. The researchers say the approach reduces infection risk and shortens recovery time. In animal studies, the device achieved precise nerve inhibition for up to six weeks, restoring normal movement patterns in models of spasticity.

The device measures less than a millimetre across and contains a flexible antenna that harvests energy from an external magnetic field. When a clinician places a handheld transmitter over the injection site, the antenna powers the micro‑circuit, which then emits brief electrical pulses to the surrounding nerve fibers. Because the system does not store energy internally, it eliminates the need for a battery. The researchers designed the circuitry to respond only to the specific frequency of the external transmitter, preventing accidental activation.

Can This Technology Replace Traditional Neuromodulation Surgery?

Lead engineer Dr Aisha Al‑Mansoor explained that the device’s material is biocompatible and degrades harmlessly after a predetermined period. „We wanted a solution that could be placed with a simple needle and then disappear once its therapeutic window closes,” she said. The team also incorporated a safety protocol that shuts down stimulation if abnormal patterns are detected, adding an extra layer of protection for patients.

The prospect of a needle‑based nerve modulator raises questions about its suitability for long‑term conditions. While early data are encouraging, the researchers acknowledge that human trials are needed to confirm durability and efficacy. „Our animal models show consistent results, but human nerves are more complex,” noted Professor Omar Haddad, who oversaw the clinical collaboration. He added that regulatory approval will hinge on demonstrating that the device can reliably target specific nerve bundles without off‑target effects.

If successful, the technology could shift the paradigm for treating chronic neuropathic pain, Parkinsonian tremor, and post‑stroke spasticity. Patients might avoid the scars and risks associated with implanted pulse generators. Moreover, the ability to turn the device on and off externally offers clinicians unprecedented control over dosing, potentially improving outcomes.

Frequently Asked Questions

How is the device implanted? A clinician injects the device through a thin needle directly adjacent to the target nerve. The procedure takes only a few minutes and can be performed under local anesthesia.

What happens after the therapeutic period ends? The device is engineered to dissolve harmlessly within months, leaving no permanent foreign material in the body. No surgical removal is required.

When will human trials begin? The research team plans to submit an application to regional health authorities later this year, aiming to start a Phase I trial in early 2027.